MetaCap

OS Therapies (OSTX) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OS Therapies (OSTX) has outperformed Spero Therapeutics (SPRO) over the past year, losing 53.0% versus a loss of 67.9%. Spero Therapeutics is the larger company by market cap ($43.2 million vs $42.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OSTX-53.04%SPRO-67.88%
+36%-18%-73%
Nov 21, 20251 yearNov 20, 2026
OSTX-79.92%SPRO-43.36%
+141%+25%-92%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OSTX versus SPRO key metrics
MetricOSTXSPRO
Share price$0.803$0.742
Market cap$42.00M$43.23M
1-day change-2.12%-10.20%
YTD return-42.64%-68.15%
1-year return-53.04%-67.88%
5-year return—-95.09%
Forward P/E2.29—
EPS (TTM)$-1.08$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$66.80M
Revenue growth (YoY)—+39.24%
Net income (latest FY)$-28.75M$8.57M
Operating margin—9.45%
Net margin—12.83%
52-week high$2.25$3.08
52-week low$0.58$0.73
Distance from 52-week high-64.31%-75.91%
Analyst consensusstrong_buynone
Avg. price target upside+958.53%+573.85%
Average volume722.66K530.46K
Shares outstanding52.30M58.26M
Employees425
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OSTX has outperformed SPRO by 14.8 percentage points over the past year.

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

OSTX vs SPRO FAQ

Which is bigger, OS Therapies or Spero Therapeutics?

Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $42.00M for OS Therapies (OSTX).

Which stock has performed better over the past year, OSTX or SPRO?

OSTX returned -53.04% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.

Are OS Therapies and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons